SINTX Technologies to Showcase Silicon Nitride Tech at H.C. Wainwright Conference
Event summary
- SINTX Technologies will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14–16, 2026.
- Gregg Honigblum (CIO) and Ryan Elmore (President) will deliver a company presentation and meet with investors.
- The presentation will focus on the commercialization of the FDA-cleared SINAPTIC® Foot & Ankle Implant System and contract manufacturing activities.
- SINTX aims to highlight strategic initiatives to broaden commercial opportunities and support long-term shareholder value.
The big picture
SINTX Technologies is positioning itself as a key player in the advanced ceramics and biomaterials sector, leveraging its proprietary silicon nitride technology. The company's focus on commercializing its FDA-cleared SINAPTIC® Foot & Ankle Implant System and expanding contract manufacturing activities aligns with broader industry trends toward specialized medical devices and high-value applications. The presentation at the H.C. Wainwright conference provides a platform to showcase these efforts to potential investors and partners.
What we're watching
- Commercialization Pace
- How quickly SINTX can expand adoption of its silicon nitride technology in medical applications.
- Contract Manufacturing
- Whether the growth in contract manufacturing activities will offset potential revenue fluctuations.
- Strategic Initiatives
- The impact of new strategic initiatives on broadening commercial opportunities and long-term shareholder value.